Indivior Pharmaceuticals, Inc. (INDV)
Indivior Pharmaceuticals Inc. operates as a holding company, primarily engaged in the research, production, and distribution of buprenorphine-based prescription medications designed to treat opioid dependence. Its product lineup features key pharmaceuticals such as Suboxone Film, Suboxone Tablet, and Subutex Tablet. The company organizes its business into several geographical regions: the United States, the United Kingdom, and the broader international market. Established on September 26, 2014, its corporate headquarters are located in North Chesterfield, Virginia.
Sector: Pharmaceutical Preparations
Industry: Drug Manufacturers - Specialty & Generic
Indivior Pharmaceuticals Inc
NASDAQ:INDVHealthcare · Drug Manufacturers - Specialty & Generic
+0.34%$35.37
AH$36.00+1.78%vs close
Mkt Cap$4.17B
Float116.56M
O/S118.04M
Vol
$ Vol
RVOL
Inst Own-
SI8.1%
Earnings
Dilution
| Form | Description | Links | |
|---|---|---|---|
| 10-Q | |||
| 425 | |||
| 8-K | |||
| 8-K | |||
| 425 | |||
| 8-K | |||
| 13G | |||
| 425 | |||
| 8-K | |||
| 8-K | |||
| EFFECT | |||
| 424B3 | |||
| S-4/A | |||
| S-4 | |||
| 4 | |||
| 13D/A | |||
| 4 | |||
| 425 | |||
| 425 | |||
| 10-Q | |||
| 425 | |||
| 8-K | |||
| 425 | |||
| 8-K | |||
| 425 |
1-25 of 552 filings
…
Recent SEC filings with analysis
- 10-QIndivior's Q3 2026 net revenue rose 13% to $356 million with net income of $137 million versus $42 million a year ago, driven by 24% U.S.
- 8-KIndivior reported record Q3 2026 results: total net revenue of $356 million (up 13% YoY), record SUBLOCADE net revenue of $267 million (up 22%), record GAAP…
- 424B3Indivior Pharmaceuticals filed a joint proxy statement/prospectus (Form 424B3) for its all-stock merger of equals with Supernus Pharmaceuticals, with both…